There is no consistent evidence from the limited number of studies that SERMs reduce the size of fibroids or improve clinical outcomes. Further studies are required to establish evidence of benefit of SERMs in treating women with uterine fibroids. This updated review did not find any new study for inclusion.
Raloxifene prevents the growth of uterine leiomyomas in premenopausal women.
To evaluate the effects of raloxifene administration on uterine leiomyoma size in premenopausal women.
                Prospective, randomized, open-label, controlled clinical trial.
                Tertiary care unit, University of Vienna, Austria.
                Twenty-five premenopausal women with uterine leiomyomas.
                Three months of treatment with raloxifene (180 mg/d) or no treatment.
                Baseline to end point percent change difference in leiomyoma volume between the therapy and control groups.
                Raloxifene treatment prevented the progression of uterine leiomyomas. Compared with no medical intervention, raloxifene resulted in a decrease of myoma volume. Raloxifene was clinically well tolerated. No significant differences were detected in symptoms related to leiomyomas and hormonal status.
                In premenopausal women, high-dose raloxifene is well tolerated and inhibits the growth of leiomyomas.